Last edition
News about "BioXcel Therapeutics"
Teva Plans Acquisition of Novel Neuroscience Product
Teva plans to acquire BXCL501, a novel dexmedetomidine sublingual film under the US Food and Drug Administration (FDA) review for potential at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder.
BioXcel Therapeutics | 01/09/2026 | By News Bureau
BioXcel Therapeutics Announces FDA Acceptance of Supplemental NDA for IGALMI
BioXcel Therapeutics receives FDA acceptance for supplemental NDA of IGALMI, targeting acute agitation in bipolar disorder and schizophrenia for potential at-home treatment use.
BioXcel Therapeutics | 02/04/2026 | By News Bureau | 292
BioXcel Therapeutics Announces FDA Acceptance of Supplemental NDA for IGALMI
BioXcel Therapeutics receives FDA acceptance for supplemental NDA of IGALMI, targeting acute agitation in bipolar disorder and schizophrenia for potential at-home treatment use.
BioXcel Therapeutics | 02/04/2026 | By News Bureau | 292
BioXcel to develop drugs in oncology
BioXcel shapes entirely claimed auxiliary OnkosXcel to foster prescriptions centered in oncology
BioXcel Therapeutics | 21/04/2022 | By Sudeep Soparkar | 981
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy